Adjuvant Chemotherapy in Early Breast Cancer: Optimal and Suboptimal Anthracycline-Containing Regimens

被引：0
作者：
Giorgio Cocconi
机构：
[1] University Hospital,Italian Oncology Group for Clinical Research (GOIRC), Medical Oncology Division
来源：
Breast Cancer Research and Treatment | 2003年 / 80卷
关键词：
adjuvant chemotherapy; anthracycline; anthracycline-containing regimens; breast carcinoma; CMF; early breast carcinoma; overview;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We hypothesized that the advantage of adjuvant anthracycline-containing regimens over the conventional CMF combination found by the Early Breast Cancer Trialists' Collaborative Group overview may depend on the 'additive' or 'substitutive' nature of the administration of anthracycline in the experimental arm. The aim of this study was to explore this hypothesis.
引用
收藏
页码：313 / 320
页数：7
相关论文
共 315 条
[1]  
Thompson SG(1998)Polychemotherapy for early breast cancer: an overview of randomised trials Lancet 352 930-942
[2]  
Fisher B(1994)Why sources of heterogeneity in metaanalyses should be investigated BMJ 309 1351-1355
[3]  
Redmond C(1989)Doxorubicincontaining regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience J Clin Oncol 7 572-582
[4]  
Wickerham DL(1995)CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study) Br J Cancer 71 1283-1287
[5]  
Bowman D(1991)Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes J Clin Oncol 9 1124-1130
[6]  
Schipper H(2001)The Mam-1 GOCSI trial: a randomised trial with factorial design of chemo-endocrine adjuvant treatment in nodepositive (N+) early breast cancer Proceed ASCO 20 27a-839
[7]  
Wolmark N(1991)Adriamycin based combination chemotherapy significantly improves overall survival in high risk premenopausal breast cancer patients Breast Cancer Res Treatment 11 166-1145
[8]  
Sass R(1995)Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study J Clin Oncol 13 831-2659
[9]  
Fisher ER(1996)Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration J Clin Oncol 14 1136-45
[10]  
Jochisem P(1998)CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial INT 0102 Proceed ASCO 17 1a-2288
12345678910